An interventional study of • Laser Speckle Flowgraphy (LSFG) and • Optical Coherence Tomography (OCT) in Diabetes Mellitus, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Diabetes Mellitus by Medical University of Vienna — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus · Medical University of Vienna.
Among the 13 studies in Diabetes Mellitus by Medical University of Vienna, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 13th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 13 studies in Diabetes Mellitus by Medical University of Vienna is open now, in 1 country.
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 18 across the 10 interventional studies, 51 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Diabetes Mellitus by Medical University of Vienna, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurements of the Ocular Blood Flow and Retinal Oxygen Extraction are performed.
Device: • Laser Speckle Flowgraphy (LSFG) · Device: • Optical Coherence Tomography (OCT) · Device: • Optical Coherence Tomography Angiography (OCT-A)
Laser Speckle Flowgraphy (LSFG)
• Optical Coherence Tomography (OCT)
• Optical Coherence Tomography Angiography (OCT-A)
Ocular blood flow (LSFG)
Ocular Blood Flow measured by Laser Speckle Flowgraphy (LSFG) in arbitrary units
Time frame: From enrollment to last study day (=5-11 weeks)
Retinal vessel diameter
Retinal vessel diameter with DVA
Time frame: From enrollment to last study day (=5-11 weeks)
Retinal oxygen saturation
Retinal oxygen saturation with DVA
Time frame: From enrollment to last study day (=5-11 weeks)
Retinal oxygen extraction
Retinal oxygen extraction will be calculated from measurements of ocular blood flow and retinal oxygen saturation. The calculation will be based on a formula integrating these parameters to estimate retinal oxygen extraction. Unit of Measure: Arbitrary units
Time frame: From enrollment to last study day (=5-11 weeks)
Oxygen and carbon dioxide partial pressure in arterialized blood
Oxygen and carbon dioxide partial pressure in arterialized blood
Time frame: From enrollment to last study day (=5-11 weeks)
Central retinal thickness
Central retinal thickness with OCT
Time frame: From enrollment to last study day (=5-11 weeks)
Retinal nerve fiber layer thickness
Retinal nerve fiber layer thickness with OCT
Time frame: From enrollment to last study day (=5-11 weeks)
Retinal and choroidal microvasculature
Retinal and choroidal microvasculature with OCT-A
Time frame: From enrollment to last study day (=5-11 weeks)
Capillary blood glucose level
Capillary blood glucose level in mg/dL
Time frame: From enrollment to last study day (=5-11 weeks)
Autonomic and sensomotoric neuropathy measurements
Short-term spectral analysis of Heart rate variability (HRV) is obtained from recordings consisting of 256 seconds of artifact free recordings. Parameters of frequency-domain HRV are measured within the low-frequency band and high-frequency band, as well as total spectral variability. Outcome variables are spectral power (ms2) in both frequency bands as well as cumulative indices.
Time frame: From enrollment to last study day (=5-11 weeks)
Ocular perfusion pressure
Ocular perfusion pressure is calculated from systemic blood pressure and intraocular pressure. Unit of measurement: mmHg
Time frame: From enrollment to last study day (=5-11 weeks)
Intraocular pressure
Intraocular pressure
Time frame: From enrollment to last study day (=5-11 weeks)
Systemic hemodynamics - Blood pressure
Systolic and diastolic blood pressure is measured. Unit: mmHg
Time frame: From enrollment to last study day (=5-11 weeks)
Schirmer I Test
Schirmer I Test is performed. Unit of measuremnt: mm
Time frame: From enrollment to last study day (=5-11 weeks)
Finger sweat sampling
Finger sweat samples will be collected using stamped-out filter paper applied to the fingertip under standardized conditions. Samples will be analyzed using an untargeted multi-omics approach. Proteomic, eicosadomic, and metabolomic profiles will be assessed using high-resolution mass spectrometry platforms. Unit of Measure: Arbitrary units (normalized intensity values)
Time frame: From enrollment to last study day (=5-11 weeks)
Systemic hemodynamics - Heart rate
Heart rate is measured. Unit: Hz
Time frame: From enrollment to last study day (=5-11 weeks)
Systemic hemodynamics - Oxygen saturation
Oxygen saturation is measured. Unit: %
Time frame: From enrollment to last study day (=5-11 weeks)
Started Nov 2025 (actual). Primary completion is estimated for May 2026, 5 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →